Phase II Study of Imatinib Mesylate in Chordoma.

Trial Profile

Phase II Study of Imatinib Mesylate in Chordoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Germ cell and embryonal neoplasms
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 17 Feb 2012 Results reported in the Journal of Clinical Oncology indicate that imatinib has some antitumor activity in this orphan disease and is worthy of further investigation.
    • 02 Sep 2011 Additional location (Switzerland) identified as reported by ClinicalTrials.gov.
    • 26 Feb 2009 Actual patient number (55) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top